Panhematin Less Costly Treatment Option for AIP Patients in US, Study Finds
Treatment with Panhematin (hemin for injection) is associated with a 78% lower average annual total cost of care compared with Givlaari (givosiran) in people with acute intermittent porphyria (AIP) in the U.S., a study reports. Panhematin-associated cost savings were greatest for AIP patients with one acute…